Alex Denner

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Sarissa Capital Management 8 1,025,000 10 1,025,000 1,025,000 5.5%
Alexander J. Denner, Ph.D 8 1,025,000 10 1,025,000 1,025,000 5.5%
Sarissa Capital Offshore Master Fund 458,766 9 458,766 11 458,766 2.5%
Sarissa Capital Domestic Fund 566,234 9 566,234 11 566,234 3.0%
Alex Denner
Alex Denner
Sarissa Capital Management

Page 1 of 7 – SEC Filing

CUSIP No.  67001K202
Page 1 of  7 Pages

Washington, D.C. 20549

Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Novelion Therapeutics Inc.
(Name of Issuer)
Common Stock, without par value
(Title of Class of Securities)
(CUSIP Number)
Mark DiPaolo
General Counsel
Sarissa Capital Management LP
660 Steamboat Road
Greenwich, CT 06830
With a copy to:
Russell Leaf
Willkie Farr & Gallagher LLP
787 Seventh Avenue
New York, New York 10019
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
June 29, 2017
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.
Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See Rule 13d-7 for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be  subject to all other  provisions of the Act  (however, see the Notes).
Follow Novelion Therapeutics Inc. (NASDAQ:NVLN)